



Press Release

 Nanotis

October 31, 2024  
Eiken Chemical Co., Ltd.  
Nanotis Corporation

---

## **Eiken Chemical, a Pioneer in Clinical Diagnostics, Invests in Nanotis, a Startup Developing Saliva-Based Infectious Disease Digital Testing Technology in a Seed 2 Round**

---

TOKYO, Japan – October 31, 2024 – Eiken Chemical Co., Ltd. (Headquarters: Taito-ku, Tokyo; President & CEO: Tsugunori Notomi), a pioneer in clinical diagnostics, has announced its investment in Nanotis Corporation (Headquarters: Shibuya-ku, Tokyo; CEO & Founder: Lisa Sakashita), a startup collaborating with the University of Tokyo, developing next-generation saliva-based digital diagnostic devices for infectious diseases. The investment was made as part of the Seed 2 round through a third-party allocation of Series B preferred stock.

### ■ **Background and Objective**

Nanotis is a startup founded in 2016 collaborating with the University of Tokyo. With the mission to "shape a world free from fear of infections," the company is engaged in the research and development of accurate, rapid, simple, and affordable digital diagnostic devices. Its patented core technology, Nucleic Acid Navigated Optically Traceable Immuno-Sensing (NANOTIS method), is the first in the world to integrate the concept of "concentration" using dielectrophoresis into detection technology, offering a revolutionary approach.



**Nanotis** Core Technology **NANOTIS Method**  
**Nucleic Acid Navigated Optically Traceable Immuno-Sensing**

- Next-Gen infectious disease testing platform technology, that is neither PCR or immunochromatography
- World's first: integration of concentration using dielectrophoresis with detection technology, achieving high sensitivity
- Theoretically equivalent approach to PCR, but with greater speed, simplicity, and cost-effectiveness

Saliva  
Ultra rapid (3 minutes)  
Simple  
Affordable  
Digital/Instant data collection

Patent granted

**Concentration & Visualization of Influenza virus\***  
\*Inactivated influenza virus was used in the Proof-of-Concept study

The product concept illustrations in this document are based on the current product vision and are subject to change based on future developments. The actual specifications may differ from what is depicted in this document.

Since its Seed finance in 2022, Nanotis has advanced Proof-of-Concept (PoC) studies in the laboratory and successfully demonstrated rapid detection of its first target virus, influenza. The NANOTIS method has the potential to be applied not only to infectious diseases but also to a wide range of biological particles. Its rapid results, which can be compiled in real-time, suggest potential future applications in disease surveillance and telemedicine, aligning with the growing field of digital health. Nanotis' technology has gained international recognition, including being selected by MedTech Innovator, the world's largest life science accelerator, as one of the 20 APAC companies for 2024.

Eiken Chemical Co., Ltd., established in 1939, has been a pioneering R&D-focused company offering excellent products and services in the field of clinical diagnostics. It holds the world's largest market share for fecal occult blood test reagents and has received international recognition for its proprietary gene amplification technology, the "LAMP method." During the COVID-19 pandemic, this technology was adopted on the frontlines of healthcare, significantly contributing to rapid testing. In its long-term plan "EIKEN Vision 2030," the company aims to "create the future of testing" and promote global health and a sustainable society, with a particular focus on establishing simpler infectious disease testing techniques.

Through this capital alliance, Eiken Chemical and Nanotis aim to collaborate as key partners in advancing the NANOTIS method. Our shared objective is to create next-generation diagnostic kits that will be accessible to anyone, anytime, anywhere. The initial step involves conducting



preclinical studies with patient samples to validate the NANOTIS technology. Concurrently, we will work on miniaturizing the system and lowering costs to develop prototypes for mass production.

Looking ahead, we plan to build a comprehensive collaboration that includes the development of an infectious disease database system grounded in Nanotis' digital technology, with an eye towards applications in the digital health sector. Additionally, we aim to broaden the scope of our platform technology to cover all biological particles, not just infectious diseases. This initiative will ultimately contribute to the creation of diagnostic devices and services that genuinely enhance healthcare.

## ■ Comments

### **Eiken Chemical President & CEO Tsugunori Notomi**

"We see the NANOTIS method as a groundbreaking technology with the potential to redefine POC Testing, offering instant results far beyond the capabilities of conventional methods. We are excited to collaborate with Nanotis to bring this innovation to life."

### **Nanotis Corporation CEO, Founder Lisa Sakashita**

"It is truly an honor to receive such high recognition from Eiken Chemical, a leader in clinical diagnostics. With the synergy between the two companies, I am confident we will be able to accelerate both our research and business development."

## ■ Method of Share Acquisition

Eiken Chemical acquired all Series B preferred shares issued by Nanotis on October 29, 2024

## ■ About Nanotis

- Name: Nanotis Corporation
- CEO, Founder : Lisa Sakashita
- Headquarters: 5-50-13 Yoyogi Shibuya-ku Tokyo 151-0053
- Joint Research Laboratory: Building 4, Faculty of Engineering, 7-3-1 Hongo Bunkyo-ku Tokyo 113-8656



- Laboratory: Yushima and Surugadai Campus, Institute of Science Tokyo, 1-5-45 Yushima Bunkyo-ku Tokyo 113-8510 (previously, Tokyo Medical and Dental University Innovation Park)
- Established: June 6, 2016
- Capital: 100 million yen
- Business Activities: Research and development of rapid infectious disease testing devices
- Website: <http://nanotis.net/>
- Concept video: <https://vimeo.com/880363397>

## ■ Contacts

Eiken Chemical  
Sustainability Department  
TEL: 03(5846)3379  
E-mail: [koho@eiken.co.jp](mailto:koho@eiken.co.jp)  
Website: <https://www.eiken.co.jp>

Nanotis Corporation  
Public Relations  
E-mail: [info@nanotis.net](mailto:info@nanotis.net)